Mycoplasma

Mycoplasma Testing Market worth $1,095 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 11, 2020
Sexually transmitted diseases and infections, Mollicutes, Infectious causes of cancer, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Natural sciences, Assay, Taxa

The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019

Key Points: 
  • The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019
    The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service.
  • Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing.
  • Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
    The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.
  • In 2019, North America accounted for the largest share of the global mycoplasma testing market.

Global Mycoplasma Testing Market Size by Product, by Geographic Scope, by End-user, and Forecast

Retrieved on: 
Tuesday, November 10, 2020
Other Manufacturing, Medical devices, Medical Supplies, Clinical trials, Manufacturing, Other Health, Biotechnology, Health, Science, Other Science, Articles, Business process, Sexually transmitted diseases and infections, Bacterial vaginosis, Infertility, Mycoplasma, Market analysis, Market research, Trend

The mycoplasma testing market is poised to grow by USD 445.57 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.

Key Points: 
  • The mycoplasma testing market is poised to grow by USD 445.57 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201110005757/en/
    Technavio has announced its latest market research report titled Global Mycoplasma Testing Market 2020-2024 (Graphic: Business Wire)
    Worried about Your Business amidst COVID-19 Impact?
  • The report on the mycoplasma testing market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The mycoplasma testing market analysis includes product segment and geography landscape.

Global Treatment and Diagnosis of Sexually Transmitted Diseases Market Report 2020 with Profiles of Abbott Laboratories, AbbVie, Novartis, Pfizer, and Thermo Fisher Scientific

Retrieved on: 
Wednesday, October 21, 2020
Articles, Medicine, Health, Disease transmission, Mycoplasma, RTT, Sexually transmitted infection, Disease, Antibiotic

DUBLIN, Oct. 21, 2020 /PRNewswire/ -- The "Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 21, 2020 /PRNewswire/ -- The "Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases" report has been added to ResearchAndMarkets.com's offering.
  • Market data in value terms is provided at global, regional, and country levels for disease areas and treatment by drug class.
  • Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.
  • It forecasts the global market by drug class for the treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals, and other treatments.

Global Mycoplasma Testing Market (2020 to 2024) - Featuring Agilent Technologies, ATCC & Becton Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 28, 2020
Health, General Health, Sexually transmitted diseases and infections, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Medical specialties, Health, Clinical medicine

The "Global Mycoplasma Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Mycoplasma Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The mycoplasma testing market is poised to grow by $ 445.57 million during 2020-2024 progressing at a CAGR of 11% during the forecast period.
  • The reports on mycoplasma testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by the increasing focus on R&D of biopharmaceuticals, increasing initiatives and funding for mycoplasma testing and rise in adoption of real-time mycoplasma testing.

AHF Rings Alarm Over Nationwide Shortage of STD Test Kits

Retrieved on: 
Friday, September 25, 2020
AIDS, Health, Medical devices, Consumer, Infectious diseases, Hospitals, Gay & Lesbian, RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Chlamydiae, Mycoplasma, Sexually transmitted infection, Chlamydia, AIDS Healthcare Foundation, Clinical medicine, Gonorrhea, Health, Medical specialties

AIDS Healthcare Foundation ( AHF ) is raising alarm bells over an extreme nationwide shortage of test kits and laboratory supplies for sexually transmitted infections (STIs, often also referred to as sexually transmitted diseases or STDs), most notably, for chlamydia and gonorrhea nucleic amplification tests (CT/GC NAAT).

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) is raising alarm bells over an extreme nationwide shortage of test kits and laboratory supplies for sexually transmitted infections (STIs, often also referred to as sexually transmitted diseases or STDs), most notably, for chlamydia and gonorrhea nucleic amplification tests (CT/GC NAAT).
  • The CDCs letter also offers Considerations for prioritizing STI testing if test kits are in short supply.
  • AHF, which operates 24 free STD testing and treatment centers, also known as AHF Wellness Centers , in nine states and Washington, D.C., has experienced the test kit shortages firsthand over the past two weeks.
  • The test kit shortage, due in part to supply chain interruptions caused by the pandemic, comes at a crucial and inopportune time.

COVID-19 Recovery Analysis: Assisted Reproductive Technology Market | Increase in Rate of Infertility and Obesity-Related Cases to Boost the Market Growth | Technavio

Retrieved on: 
Wednesday, September 23, 2020
Health, Biotechnology, Fertility medicine, Human reproduction, Infertility, Mycoplasma, Women's health, Reproductive technology, Articles

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • The increase in rate of infertility and obesity-related cases has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Assisted Reproductive Technology Market 2020-2024: Segmentation
    Assisted Reproductive Technology Market is segmented as below:

Purchase, George & Murphey, P.C. To Sponsor The New Blossoms New Life Foundation's 2020 Charity Fundraiser

Retrieved on: 
Monday, September 21, 2020
Fertility medicine, Infertility, Mycoplasma, Women's health, Raffles, Blossoms, Mentorship, Human activities, Human Nature, Articles

are pleased to announce that they will partner with and sponsor the New Blossoms New Life Foundation's 2020 charity fundraiser, "This, That, or the Other," a series ofweekly raffles taking place via Facebook beginningSunday, September 27th, and lasting through the end of the year.

Key Points: 
  • are pleased to announce that they will partner with and sponsor the New Blossoms New Life Foundation's 2020 charity fundraiser, "This, That, or the Other," a series ofweekly raffles taking place via Facebook beginningSunday, September 27th, and lasting through the end of the year.
  • The New Blossoms New Life Foundation provides financial assistance and emotional support to couples challenged with infertility with the goal of helping them have a child.
  • New Blossoms New Life Foundation awards grants for costly fertility treatments and provides mentoring, counseling, and community education.
  • In 2010, after nearly two decades of success in courtrooms throughout Erie and northwest Pennsylvania, Eric Purchase and Tim George founded Purchase, George & Murphey, P.C.

STD Testing Market Size to Hit $133.93 Billion by 2025; Growing prevalence of STD, National Screening Programs have Fueled the Growth

Retrieved on: 
Thursday, September 3, 2020
RTT, Disease transmission, Mycoplasma, Sexually transmitted infection, Women's reproductive health in the United States

Growing prevalence of STD, implementation of national screening programs, and supporting reimbursement for STD testing have fueled the growth of the global STD testing market .

Key Points: 
  • Growing prevalence of STD, implementation of national screening programs, and supporting reimbursement for STD testing have fueled the growth of the global STD testing market .
  • Based on testing type, the laboratory testing segment generated the largest share in 2017, accounting for more than four-fifths of the total market.
  • Rise in incidence of sexually transmitted diseases across the region has spurred the growth of the market in the region.
  • Moreover, growing healthcare awareness and increase in responsiveness for early screening or diagnosis of the sexually transmitted diseases have accelerated the growth in more than one way.

COVID-19 Pandemic Impact on Global Mycoplasma Testing Market 2020-2024 | Technavio

Retrieved on: 
Wednesday, August 26, 2020
Medical devices, Health, Sexually transmitted diseases and infections, Health, Infectious causes of cancer, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Trend, Forecast period, Pharmaceutical industry, Marketplace, Articles

With the surging growth of COVID-19 pandemic, the Health Care market is anticipated to have a direct impact during the forecast period.

Key Points: 
  • With the surging growth of COVID-19 pandemic, the Health Care market is anticipated to have a direct impact during the forecast period.
  • View market snapshot before purchasing
    Growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies has been an instrumental factor in influencing the growth of mycoplasma testing market.
  • Other market drivers include increasing initiatives and funding for mycoplasma testing and rise in adoption of real-time mycoplasma testing.
  • Key Considerations for Market Forecast:
    Get more insights about the global trends impacting the future of mycoplasma testing market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR43492
    The market is fragmented, and the degree of fragmentation will accelerate during the forecast period.

Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis

Retrieved on: 
Thursday, August 20, 2020
RTT, Sexually transmitted diseases and infections, Medical specialties, Clinical medicine, Probiotics, Mycoplasma, Organ systems, Bacterial vaginosis, Clindamycin

DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).

Key Points: 
  • DARE-BV1 is a novel thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% that is being evaluated as a one-time vaginally administered treatment for bacterial vaginosis (BV).
  • This proof of concept study suggests that DARE-BV1 has the potential to be a highly effective treatment option for bacterial vaginosis, the most common cause of vaginal symptoms among women, said David Friend, PhD, Chief Scientific Officer of Dar Bioscience.
  • Alarmingly, as many as 50% of women treated for bacterial vaginosis will experience a recurrence within 12 months of treatment, which underscores the need for more effective treatment options for women.
  • 5
    Dar recently announced the initiation of the DARE-BVFREE study, a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial vaginosis.